Related Experiment Video

Updated: Feb 26, 2026

Monitoring Leucine-Rich Repeat Containing 8 Channel (LRRC8/VRAC) Activity Using Sensitized-Emission Förster Resonance Energy Transfer (SE-FRET)
08:54

Monitoring Leucine-Rich Repeat Containing 8 Channel (LRRC8/VRAC) Activity Using Sensitized-Emission Förster Resonance Energy Transfer (SE-FRET)

Published on: August 9, 2024

958

NLRC5/CITA: A Key Player in Cancer Immune Surveillance

Sayuri Yoshihama1, Saptha Vijayan2, Tabasum Sidiq2

  • 1Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M University, College Station, TX 77843, USA; Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.

Trends in Cancer
|July 19, 2017
PubMed

Insights

NLRC5, a key regulator of MHC class I, is crucial for anti-cancer immunity. Its reduced activity in cancer cells impairs immune surveillance, leading to tumor growth and poor patient outcomes.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Cancer cells evade immune surveillance for tumor growth.
  • Loss of MHC class I is a common immune evasion strategy.
  • NLRC5 (MHC class I transactivator) is a key coactivator for MHC class I genes.

Purpose of the Study:

  • To review the role of NLRC5 in cancer immune evasion.
  • To discuss the implications of NLRC5 dysfunction in cancer.
  • To explore future research directions for NLRC5 in oncology.

Main Methods:

  • Literature review of genetic studies on NLRC5.
  • Analysis of NLRC5's role in MHC class I expression.
  • Examination of NLRC5's impact on cytotoxic T cell activation.

Main Results:

  • Reduced NLRC5 expression/activity is linked to cancer immune evasion.
  • Mechanisms include promoter methylation, copy number loss, and somatic mutations.
  • NLRC5 dysfunction correlates with defective MHC class I, impaired T cell response, and poor prognosis.

Conclusions:

  • NLRC5 is a critical factor in anti-cancer immunity.
  • Dysregulation of NLRC5 contributes significantly to cancer progression.
  • Targeting NLRC5 presents potential therapeutic avenues in cancer treatment.
Keywords:
CITAMHC class INLRC5cancerimmune evasion

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

21.0K

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.1K